Miscellaneous immune disorders:
Indications for: FIRDAPSE
Lambert-Eaton myasthenic syndrome (LEMS) in patients aged ≥6yrs.
Adults and Children:
<6yrs: not established. ≥6yrs (<45kg): Initially 5–15mg daily in 3–4 divided doses; may increase by 2.5mg every 3 or 4 days (max single dose: 10mg; max total: 40mg/day). ≥6yrs (≥45kg): Initially 15–30mg daily in 3–4 divided doses; may increase by 5mg every 3 or 4 days (max single dose: 20mg; max total: 80mg/day). Hepatic or renal impairment (CrCl 15–90mL/min), NAT2 poor metabolizers: 15mg daily (for patients ≥45kg) and 5mg daily (for patients <45kg) in 3 divided doses. Patients who require dosage <5mg increments, have difficulty swallowing, or require feeding tubes: may prepare a 1mg/mL oral suspension; see full labeling.
History of seizures.
Consider dose reduction or discontinuation if seizure occurs. Discontinue and treat if anaphylaxis occurs. Hepatic or renal impairment: monitor; adjust dose or discontinue as needed. N-acetyltransferase 2 (NAT2) poor metabolizers. Elderly. Pregnancy. Nursing mothers.
Potassium channel blocker.
Concomitant drugs that lower seizure threshold may increase seizure risk. Additive effects when concomitant drugs with cholinergic effects (eg, direct or indirect cholinesterase inhibitors).
Paresthesia, upper RTI, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, muscle spasms; seizures, hypersensitivity.
Generic Drug Availability:
Tabs—60, 240; Blister packs—10, 120